PRIMECAP Management's top holdings (May 2025) include Lilly(Eli) & Co (LLY), a major player in the pharmaceutical industry.

PRIMECAP Management is an investment management company that serves a diverse range of clients. The firm focuses on bottom-up, fundamental research to identify long-term investment opportunities. Their investment approach spans various sectors and geographies.

Lilly(Eli) & Co

Eli Lilly and Company is a global pharmaceutical company that develops, manufactures, and markets pharmaceutical products. Its key products include treatments for diabetes, cancer, and autoimmune diseases. The market capitalization of Lilly(Eli) & Co is $838.53B, with PRIMECAP Management's position currently valued at $15.06B. Analysts have set a price target of $1.02K for Lilly(Eli) & Co. The company's discounted cash flow analysis suggests a value of $369.54 per share.

Here's an overview of PRIMECAP Management's trades in Lilly(Eli) & Co:

Sony Corporation. - ADR

Sony Corporation is a global conglomerate involved in electronics, gaming, entertainment, and financial services. The company is known for its PlayStation gaming consoles, movies, music, and various electronic products. This holding in PRIMECAP Management's portfolio is currently worth $10.81B.

Here's an overview of PRIMECAP Management's trades in Sony Corporation. - ADR:

Boston Scientific Corp.

Boston Scientific Corporation develops, manufactures, and markets medical devices used in a range of interventional medical specialties. These include cardiology, electrophysiology, endoscopy, and urology. The company's market cap stands at $150.72B, while the current value of PRIMECAP Management's holding is $3.8B. The analyst price target for Boston Scientific Corp. is $117.2, and its discounted cash flow value is $61.49.

Here's an overview of PRIMECAP Management's trades in Boston Scientific Corp.:

AMGEN Inc.

Amgen Inc. is a biotechnology company that discovers, develops, manufactures, and delivers innovative human therapeutics. The company focuses on areas such as oncology, cardiovascular disease, inflammation, and bone health. AMGEN Inc. has a market capitalization of $150.99B, with PRIMECAP Management's position currently valued at $3.78B. Analysts have set a price target of $299.5 for AMGEN Inc. The company's discounted cash flow analysis suggests a value of $728.02 per share.

Here's an overview of PRIMECAP Management's trades in AMGEN Inc.:

Microsoft Corporation

Microsoft Corporation develops, licenses, and supports a range of software products, services, and devices. Its products include the Windows operating system, Office productivity suite, and Azure cloud services. Microsoft Corporation has a market capitalization of $2.91T, and the current value of PRIMECAP Management's holding is $3.77B. Analysts have set a price target of $503.0 for Microsoft Corporation. The company's discounted cash flow analysis suggests a value of $364.96 per share.

Here's an overview of PRIMECAP Management's trades in Microsoft Corporation: